DXB Chart, page-383

For some reason the ASX simply doesn't seem to get how Licensing rights, royalties and upfront payment deals create company wealth, I would like you all to look at NEU and how it was beaten around after the original deal with Acadia was announced.
Acadia actually obtained FDA approval and are doing all the gruntwork, NEU now collects ongoing 'growing' revenue (royalties and possibly milestone payments) from Acadia's sales.
NEU now has another product going through P2 trials and word is it'll be better than the original FDA approved product.
DXB's recent deal doesn't include Nth America which will be a huge feather in the cap.
This to me may be another NEU type company which is now in the ASX200 and word on the street is that they will be lucky to be around at the end of 2024 due to BP takeover, probably for triple it's current MC.